Rapport Therapeutics (RAPP) Competitors $15.22 +0.84 (+5.84%) Closing price 04:00 PM EasternExtended Trading$15.34 +0.12 (+0.79%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. TARS, IMCR, ARQT, SPRY, SDGR, OCUL, VERA, BHVN, EVO, and ETNBShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), Biohaven (BHVN), Evotec (EVO), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors Tarsus Pharmaceuticals Immunocore Arcutis Biotherapeutics ARS Pharmaceuticals Schrodinger Ocular Therapeutix Vera Therapeutics Biohaven Evotec 89BIO Tarsus Pharmaceuticals (NASDAQ:TARS) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk. Which has better valuation and earnings, TARS or RAPP? Rapport Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M9.54-$115.55M-$2.73-15.22Rapport TherapeuticsN/AN/A-$78.31M-$3.45-4.41 Do insiders & institutionals believe in TARS or RAPP? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is TARS or RAPP more profitable? Rapport Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Rapport Therapeutics' return on equity of -25.48% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-44.91% -39.72% -25.74% Rapport Therapeutics N/A -25.48%-24.63% Do analysts prefer TARS or RAPP? Tarsus Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 60.45%. Rapport Therapeutics has a consensus price target of $28.00, indicating a potential upside of 83.97%. Given Rapport Therapeutics' higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TARS or RAPP? In the previous week, Tarsus Pharmaceuticals had 7 more articles in the media than Rapport Therapeutics. MarketBeat recorded 11 mentions for Tarsus Pharmaceuticals and 4 mentions for Rapport Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 0.64 beat Rapport Therapeutics' score of 0.62 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTarsus Pharmaceuticals beats Rapport Therapeutics on 8 of the 14 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$555.53M$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-4.4120.5028.6419.75Price / SalesN/A267.15432.34182.50Price / CashN/A43.1536.0257.96Price / Book1.827.768.235.67Net Income-$78.31M-$55.11M$3.24B$257.98M7 Day Performance8.64%1.03%0.05%0.56%1 Month Performance35.89%8.54%5.65%8.88%1 Year Performance-44.80%-2.26%26.57%14.24% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.6337 of 5 stars$15.22+5.8%$28.00+84.0%-42.5%$555.53MN/A-4.41N/ANews CoverageTARSTarsus Pharmaceuticals1.8379 of 5 stars$39.93-3.0%$66.67+67.0%+44.9%$1.73B$182.95M-14.6350News CoveragePositive NewsAnalyst RevisionIMCRImmunocore1.4303 of 5 stars$32.41-1.8%$58.89+81.7%-10.9%$1.66B$310.20M-75.37320ARQTArcutis Biotherapeutics1.2721 of 5 stars$13.39-3.1%$18.80+40.4%+43.0%$1.65B$196.54M-12.88150Insider TradeSPRYARS Pharmaceuticals2.8284 of 5 stars$17.09+3.5%$31.00+81.4%+50.6%$1.62B$97.12M-106.8190News CoverageSDGRSchrodinger1.7947 of 5 stars$20.63-2.3%$33.25+61.2%-10.2%$1.55B$207.54M-7.84790Analyst ForecastOCULOcular Therapeutix3.8773 of 5 stars$9.61-0.1%$17.33+80.4%+31.6%$1.53B$63.72M-8.36230Positive NewsVERAVera Therapeutics4.226 of 5 stars$22.97-4.3%$65.00+183.0%-36.9%$1.53BN/A-7.6640Positive NewsBHVNBiohaven3.3508 of 5 stars$13.81-5.6%$58.46+323.3%-65.5%$1.49BN/A-1.48239Trending NewsEVOEvotec1.9816 of 5 stars$4.18-0.5%$5.93+41.9%-13.8%$1.49B$862.40M0.004,827ETNB89BIO1.8202 of 5 stars$10.22+0.6%$26.43+158.6%+16.8%$1.48BN/A-3.0240 Related Companies and Tools Related Companies TARS Competitors IMCR Competitors ARQT Competitors SPRY Competitors SDGR Competitors OCUL Competitors VERA Competitors BHVN Competitors EVO Competitors ETNB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
